Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Kandice E. Robertsa Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USAView further author information

Michael W. Deiningerb Division of Hematology and Hematologic Malignancies, University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USAView further author information

Gerhard C. Hildebrandtc Division of Hematology and Blood and Marrow Transplantation, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USAView further author information

Brian K. Gackenbachd Division of Blood and Marrow Transplantation, University of Louisville School of Medicine, Louisville, KY, USAView further author information

Maxwell M. Kremc Division of Hematology and Blood and Marrow Transplantation, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY, USACorrespondence[email protected]

https://orcid.org/0000-0003-3980-480X View further author information

Click to increase image sizeClick to decrease image size

Disclosure statement

GCH reports stock ownership of Bristol-Myers Squibb

Informed consent

The patient described has given consent to the inclusion of material pertaining to herself, acknowledges that she is not identifiable via the paper. We have fully anonymized the patient.

Additional information

Funding

GCH reports research support from Takeda, Pharmacyclics, Jazz, Astellas, and Incyte and stock ownership of Bristol-Myers Squibb. MWD reports research support from NIH, R01CA178397.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Information for

Open access

Opportunities

Help and information

Use of dasatinib dose-reduction periods to remedy poor surgical wound healing in Philadelphia chromosome-positive acute lymphoblastic leukemia

Disclosure statement

Informed consent

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature